SWOG clinical trial number
E1905

A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia

Closed
Phase
Published
Abbreviated Title
Phase II Azacitidine +/- MS-275 for MDS, CML (Dysplastic), and AML with Multilineage Dysplasia
Activated
10/01/2006
Participants
NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees

Leukemia

Treatment

Azacitidine MS-275